How many clinical trials are there for Obstructive Hypertrophic Cardiomyopathy?

PlainTrial tracks 4 US clinical trials for Obstructive Hypertrophic Cardiomyopathy, of which 3 are currently recruiting.

Which interventions appear most often on Obstructive Hypertrophic Cardiomyopathy trial records?

Mavacamten is the most-linked intervention name on Obstructive Hypertrophic Cardiomyopathy records (2 trial links), followed by Non-mavacamten symptomatic oHCM therapy. Names are sponsor-reported on ClinicalTrials.gov.

How do I find a recruiting trial for Obstructive Hypertrophic Cardiomyopathy?

Use the trial list filtered by Recruiting status, or visit the trial finder to search by condition and state. Always discuss with your healthcare provider.

Is this data current?

Data is from ClinicalTrials.gov. Trial status may have changed. Always verify at ClinicalTrials.gov before making participation decisions.

Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now small index

Obstructive Hypertrophic Cardiomyopathy clinical trials

Compiled by PlainTrial · August 8, 2026

3 of 4 indexed Obstructive Hypertrophic Cardiomyopathy trials are currently recruiting.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Obstructive Hypertrophic Cardiomyopathy: 4 US clinical trials tracked, 3 recruiting.

Obstructive Hypertrophic Cardiomyopathy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. The most active sponsor is Bristol-Myers Squibb, running 2 of these trials.

Enrollment posture brief

Registry condition obstructive-hypertrophic-cardiomyopathy

Volume-matched condition peers

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Open-enrollment share among volume-matched conditions near Obstructive Hypertrophic Cardiomyopathy

Obstructive Hypertrophic Cardiomyopathy lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Obstructive Hypertrophic Cardiomyopathy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

Obstructive Hypertrophic Cardiomyopathy is recruiting above its size-band peers.

3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Open and recent trials

4 total, page 1 of 1

RECRUITING 1,600 participants

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

Bristol-Myers Squibb

NCT05489705

RECRUITING 118 participants

Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Bristol-Myers Squibb

NCT06551129

RECRUITING 20 participants

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Michael Ayers

NCT06023186

COMPLETED 325 participants

Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)

National Heart, Lung, and Blood Institute (NHLBI)

NCT04603521

Phase Distribution

Phase data not available

Top Sponsors

Bristol-Myers Squibb 2 trials

Michael Ayers 1 trials

National Heart, Lung, and Blood Institute (NHLBI) 1 trials

Named interventions

Most-linked intervention names on Obstructive Hypertrophic Cardiomyopathy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Mavacamten Drug

2 trials

Non-mavacamten symptomatic oHCM therapy Drug

1 trials

mavacamten Drug

1 trials

US sites by state

Facility locations filed on Obstructive Hypertrophic Cardiomyopathy trials. A trial with sites in several states counts in each.

Maryland 2 trials

Massachusetts 2 trials

Virginia 1 trials

Kansas 1 trials

Indiana 1 trials

Illinois 1 trials

Iowa 1 trials

Hawaii 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Obstructive Hypertrophic Cardiomyopathy page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

3 Obstructive Hypertrophic Cardiomyopathy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
Bristol-Myers Squibb sponsors the most Obstructive Hypertrophic Cardiomyopathy trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Obstructive Hypertrophic Cardiomyopathy condition card totals 4 registered trials; most-linked intervention Mavacamten; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.